

## SUPPLEMENTAL REFERENCES

1. Lin JD, Chao TC, Hsueh C. Clinical characteristics of poorly differentiated thyroid carcinomas compared with those of classical papillary thyroid carcinomas. *Clin Endocrinol (Oxf)* 2007;66:224-8.
2. Jung TS, Kim TY, Kim KW, Oh YL, Park DJ, Cho BY, et al. Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma. *Endocr J* 2007;54:265-74.
3. Asioli S, Erickson LA, Righi A, Jin L, Volante M, Jenkins S, et al. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. *Mod Pathol* 2010;23:1269-78.
4. Bhargav PR, Mishra A, Agarwal G, Agarwal A, Pradhan PK, Gambhir S, et al. Long-term outcome of differentiated thyroid carcinoma: experience in a developing country. *World J Surg* 2010;34:40-7.
5. Hod R, Bachar G, Sternov Y, Shvero J. Insular thyroid carcinoma: a retrospective clinicopathologic study. *Am J Otolaryngol* 2013;34:292-5.
6. Gnemmi V, Renaud F, Do Cao C, Salleron J, Lion G, Wehmeau JL, et al. Poorly differentiated thyroid carcinomas: application of the Turin proposal provides prognostic results similar to those from the assessment of high-grade features. *Histopathology* 2014;64:263-73.
7. Lee DY, Won JK, Lee SH, Park DJ, Jung KC, Sung MW, et al. Changes of clinicopathologic characteristics and survival outcomes of anaplastic and poorly differentiated thyroid carcinoma. *Thyroid* 2016;26:404-13.
8. Skansing DB, Londero SC, Asschenfeldt P, Larsen SR, Godballe C. Nonanaplastic follicular cell-derived thyroid carcinoma: mitosis and necrosis in long-term follow-up. *Eur Arch Otorhinolaryngol* 2017;274:2541-8.
9. Yu MG, Rivera J, Jimeno C. Poorly differentiated thyroid carcinoma: 10-year experience in a Southeast Asian population. *Endocrinol Metab (Seoul)* 2017;32:288-95.
10. de la Fouchardiere C, Decaussin-Petrucci M, Berthiller J, Descotes F, Lopez J, Lifante JC, et al. Predictive factors of outcome in poorly differentiated thyroid carcinomas. *Eur J Cancer* 2018;92:40-7.
11. Ito Y, Miyauchi A, Hirokawa M, Yamamoto M, Oda H, Masuoka H, et al. Prognostic value of the 8th tumor-node-metastasis classification for follicular carcinoma and poorly differentiated carcinoma of the thyroid in Japan. *Endocr J* 2018;65:621-7.
12. Nunes da Silva T, Limbert E, Leite V. Poorly differentiated thyroid carcinoma patients with detectable thyroglobulin levels after initial treatment show an increase in mortality and disease recurrence. *Eur Thyroid J* 2018;7:313-8.
13. Bichoo RA, Mishra A, Kumari N, Krishnani N, Chand G, Agarwal G, et al. Poorly differentiated thyroid carcinoma and poorly differentiated area in differentiated thyroid carcinoma: is there any difference? *Langenbecks Arch Surg* 2019;404:45-53.
14. Akaishi J, Kondo T, Sugino K, Ogimi Y, Masaki C, Hames KY, et al. Prognostic impact of the Turin criteria in poorly differentiated thyroid carcinoma. *World J Surg* 2019;43:2235-44.
15. Wong KS, Lorch JH, Alexander EK, Marqusee E, Cho NL, Nehs MA, et al. Prognostic significance of extent of invasion in poorly differentiated thyroid carcinoma. *Thyroid* 2019;29:1255-61.
16. Kersting D, Seifert R, Kessler L, Herrmann K, Theurer S, Brandenburg T, et al. Predictive factors for RAI-refractory disease and short overall survival in PDTC. *Cancers (Basel)* 2021;13:1728.
17. Panchangam RB, Puthenveetil P, Mayilvaganan S. Prognostic impact of focal poorly differentiated areas in follicular differentiated thyroid cancer: is it a distinct entity from poorly differentiated thyroid cancer? *Indian J Surg Oncol* 2022;13:157-63.
18. Xu B, David J, Dogan S, Landa I, Katabi N, Saliba M, et al. Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases. *Histopathology* 2022;80:322-37.
19. Gubbiotti MA, Andrianus S, Sakhi R, Zhang Q, Montone K, Jalaly JB, et al. Does the presence of capsule influence prognosis in poorly differentiated thyroid carcinoma? *Hum Pathol* 2023;136:96-104.
20. Jeong SI, Kim W, Yu HW, Choi JY, Ahn CH, Moon JH, et al. Incidence and clinicopathological features of differentiated high-grade thyroid carcinomas: an institutional experience. *Endocr Pathol* 2023;34:287-97.
21. Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, Shaha A, et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. *Cancer* 2006;106:1286-95.
22. Ibrahimasic T, Ghossein R, Carlson DL, Chernichenko N, Nixon I, Palmer FL, et al. Poorly differentiated thyroid carcinoma presenting with gross extrathyroidal extension: 1986-

- 2009 Memorial Sloan-Kettering Cancer Center experience. *Thyroid* 2013;23:997-1002.
23. Ibrahimasic T, Ghossein R, Carlson DL, Nixon I, Palmer FL, Shaha AR, et al. Outcomes in patients with poorly differentiated thyroid carcinoma. *J Clin Endocrinol Metab* 2014; 99:1245-52.
24. Ibrahimasic T, Ghossein R, Carlson DL, Nixon IJ, Palmer FL, Patel SG, et al. Undetectable thyroglobulin levels in poorly differentiated thyroid carcinoma patients free of macroscopic disease after initial treatment: are they useful? *Ann Surg Oncol* 2015;22:4193-7.
25. Sabra MM, Ghossein R, Tuttle RM. Time course and predictors of structural disease progression in pulmonary metastases arising from follicular cell-derived thyroid cancer. *Thyroid* 2016;26:518-24.
26. Xu B, Ibrahimasic T, Wang L, Sabra MM, Migliacci JC, Tuttle RM, et al. Clinicopathologic features of fatal non-anaplastic follicular cell-derived thyroid carcinomas. *Thyroid* 2016;26:1588-97.
27. Xu B, Lubin DJ, Dogan S, Ghossein RA, Viswanathan K. Significance of oncocytic features in poorly differentiated thyroid carcinoma: a bi-institutional experience. *Virchows Arch* 2023;482:479-91.
28. Lee DY, Won JK, Choi HS, Park do J, Jung KC, Sung MW, et al. Recurrence and survival after gross total removal of resectable undifferentiated or poorly differentiated thyroid carcinoma. *Thyroid* 2016;26:1259-68.
29. Wong KS, Dong F, Telatar M, Lorch JH, Alexander EK, Marqusee E, et al. Papillary thyroid carcinoma with high-grade features versus poorly differentiated thyroid carcinoma: an analysis of clinicopathologic and molecular features and outcome. *Thyroid* 2021;31:933-40.
30. Ito Y, Hirokawa M, Higashiyama T, Takamura Y, Miya A, Kobayashi K, et al. Prognosis and prognostic factors of follicular carcinoma in Japan: importance of postoperative pathological examination. *World J Surg* 2007;31:1417-24.
31. Ito Y, Hirokawa M, Fukushima M, Inoue H, Yabuta T, Uruno T, et al. Prevalence and prognostic significance of poor differentiation and tall cell variant in papillary carcinoma in Japan. *World J Surg* 2008;32:1535-43.
32. Ito Y, Hirokawa M, Kihara M, Takamura Y, Kobayashi K, Miya A, et al. Prognostic value of poorly differentiated carcinoma in Japanese Society of Thyroid Surgery in a series of papillary thyroid carcinoma patients: comparison with risk classification system in Kuma Hospital. *Endocr J* 2012;59: 817-21.
33. de la Fouchardiere C, Oussaid N, Derbel O, Decaussin-Petrucci M, Fondreville ME, Wang Q, et al. Does molecular genotype provide useful information in the management of radioiodine refractory thyroid cancers? Results of a retrospective study. *Target Oncol* 2016;11:71-82.
34. Bai S, Baloch ZW, Samulski TD, Montone KT, LiVolsi VA. Poorly differentiated oncocytic (hürthle cell) follicular carcinoma: an institutional experience. *Endocr Pathol* 2015; 26:164-9.
35. Thiagarajan S, Yousuf A, Shetty R, Dhar H, Mathur Y, Nair D, et al. Poorly differentiated thyroid carcinoma (PDTC) characteristics and the efficacy of radioactive iodine (RAI) therapy as an adjuvant treatment in a tertiary cancer care center. *Eur Arch Otorhinolaryngol* 2020;277:1807-14.
36. Adam P, Kircher S, Sbiera I, Koehler VF, Berg E, Knosel T, et al. FGF-receptors and PD-L1 in anaplastic and poorly differentiated thyroid cancer: evaluation of the preclinical rationale. *Front Endocrinol (Lausanne)* 2021;12:712107.
37. Luna-Ortiz K, Hurtado-Lopez LM, Dominguez-Malagon H, Ramirez-Marin R, Zaldivar-Ramirez FR, Herrera-Gomez A, et al. Clinical course of insular thyroid carcinoma. *Med Sci Monit* 2004;10:CR108-11.
38. Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Hartl D, Lumbroso J, et al. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. *Thyroid* 2015; 25:437-44.
39. Wan Z, Wang B, Yao J, Li Q, Miao X, Jian Y, et al. Predictive factors and clinicopathological characteristics of outcome in poorly differentiated thyroid carcinoma: a single-institution study. *Front Oncol* 2023;13:1102936.
40. Thompson LDR. High grade differentiated follicular cell-derived thyroid carcinoma versus poorly differentiated thyroid carcinoma: a clinicopathologic analysis of 41 cases. *Endocr Pathol* 2023;34:234-46.